Hide Board Information

Show Board Information

PharmaCyte Biotech Inc. PMCB

Board Mod: Add me as mod

Asst Mods:

Last Post: 11/15/2023 8:10:49 AM

Board Marks: 56

Posts Today: 0

Board Views Today: 137

PharmaCyte Biotech Inc. (NASDAQ: PMCB) Stock Message Board

1. PMCB Company Profile

    

2. PMCB Time & Sales

    

3. PMCB Recent News

    

4. PMCB Filings

    

5. PMCB Financials

    

6. PMCB Buy Rating

Create New Post View All Posts Board Mark Banned

Post

Subject

Author

Posted On

820	NVLX A clinical-stage international	stocklegend	04/02/2014 10:00:40 AM
819	NVLX Pancreatic Cancer Cures?	stocklegend	04/02/2014 9:03:46 AM
818	Dr. Von Hoff is THE LEADING FIGURE in pancreatic	Tandrel	04/02/2014 9:03:17 AM
817	NVLX "We are honored that TD2 and Dr. Von Hoff	stocklegend	04/01/2014 2:25:58 PM
816	NVLX The PCRT, an affiliate of TD2, has the	stocklegend	04/01/2014 1:20:46 PM
815	NVLX Dr. Von Hoff is the one who developed	stocklegend	04/01/2014 12:14:36 PM
814	NVLX "Our Pancreatic Cancer Research Team (PCRT)	stocklegend	04/01/2014 11:29:49 AM
813	NVLX "The Nuvilex team presents us with a new	stocklegend	04/01/2014 10:15:37 AM
812	NVLX NEWS:	stocklegend	04/01/2014 9:35:17 AM
811	$NVLX - Nuvilex Enters Most Important Step of	stocklegend	04/01/2014 9:08:03 AM
810	$NVLX With live-cell encapsulation, depending on	Tandrel	04/01/2014 8:27:23 AM
809	$NVLX ~ Here's a simple Nuvilex chart:	Tandrel	04/01/2014 8:25:12 AM
808	$NVLX's live-cell encapsulation technology is a	Tandrel	04/01/2014 8:23:22 AM
807	$NVLX Investors Confidently Back Nuvilex's	stocklegend	03/31/2014 1:57:24 PM
806	$NVLX Diabetes Treatment Drives Big Increase	stocklegend	03/31/2014 1:47:30 PM
805	$NVLX After Pancreatic Cancer, Eli Lilly and	stocklegend	03/31/2014 12:48:10 PM
804	$NVLX Nuvilex Appoints Dr. Mark Rabe, a	stocklegend	03/31/2014 11:07:25 AM
803	$NVLX Nuvilex Appoints Dr. Mark Rabe, a	stocklegend	03/31/2014 10:21:04 AM
802	$NVLX Nuvilex Begins Making Moves at its	stocklegend	03/31/2014 9:47:58 AM
801	$NVLX Nuvilex's Medical Marijuana Subsidiary	stocklegend	03/31/2014 9:04:02 AM
800	$NVLX has acquired worldwide exclusive rights to	Tandrel	03/31/2014 8:45:09 AM
799	$NVLX Company info and share structure	Tandrel	03/31/2014 8:42:59 AM
798	$NVLX ~ Here's a simple Nuvilex chart:	Tandrel	03/31/2014 8:39:41 AM
797	$NVLX Nuvilex Appoints Dr. Mark Rabe, a	stocklegend	03/28/2014 3:36:50 PM
796	$NVLX Nuvilex Begins Making Moves at its	stocklegend	03/28/2014 3:35:42 PM
795	$NVLX Nuvilex's Medical Marijuana Subsidiary	stocklegend	03/28/2014 1:29:57 PM
794	$NVLX Nuvilex, Inc. Featured on Forbes:	stocklegend	03/28/2014 12:15:00 PM
793	$NVLX Nuvilex Listed in Forbes Article on	stocklegend	03/28/2014 11:33:26 AM
792	$NVLX - Nuvilex COO Talks Medical Marijuana in NY	stocklegend	03/28/2014 11:13:50 AM
791	$NVLX - Nuvilex Featured in Forbes and NY Post	stocklegend	03/28/2014 10:24:08 AM
790	$NVLX - Nuvilex Acquires Cancer Cell	stocklegend	03/28/2014 9:56:10 AM
789	$NVLX - Nuvilex Acquires Cancer Technology, Next	stocklegend	03/28/2014 9:23:52 AM
788	$NVLX Nuvilex Listed in Forbes Article on	stocklegend	03/27/2014 2:49:03 PM
787	$NVLX - Nuvilex COO Talks Medical Marijuana in NY	stocklegend	03/27/2014 1:21:34 PM
786	$NVLX - Nuvilex Featured in Forbes and NY Post	stocklegend	03/27/2014 12:51:40 PM
785	$NVLX - Nuvilex Acquires Cancer Cell	stocklegend	03/27/2014 11:44:51 AM
784	$NVLX - Nuvilex Acquires Cancer Technology, Next	stocklegend	03/27/2014 11:33:36 AM
783	$NVLX - Nuvilex Restructures its Operations to	stocklegend	03/27/2014 10:19:17 AM
782	$NVLX - Nuvilex Restructures its Operations to	stocklegend	03/27/2014 10:16:31 AM
781	$NVLX - Nuvilex Restructures to Focus on	stocklegend	03/27/2014 10:00:01 AM
780	$NVLX - Nuvilex Contracts with Inno Biologics to	stocklegend	03/27/2014 9:29:25 AM
779	$NVLX - Nuvilex Enters Most Important Step of	stocklegend	03/27/2014 9:18:58 AM
778	$NVLX Nuvilex Announces Cloning of Cells for	stocklegend	03/26/2014 3:14:42 PM
777	$NVLX Nuvilex Completes Acquisition of	stocklegend	03/26/2014 2:44:03 PM
776	$NVLX Nuvilex Accelerates Development of	stocklegend	03/26/2014 1:52:33 PM
775	$NVLX Nuvilex's Acquisition of Diabetes	stocklegend	03/26/2014 12:56:48 PM
774	$NVLX Investors Confidently Back Nuvilex's	stocklegend	03/26/2014 12:07:48 PM
773	$NVLX Diabetes Treatment Drives Big Increase	stocklegend	03/26/2014 11:38:39 AM
772	$NVLX After Pancreatic Cancer, Eli Lilly and	stocklegend	03/26/2014 10:43:47 AM
771	$NVLX Nuvilex and Eli Lilly Going Head to	stocklegend	03/26/2014 10:04:08 AM

Newer

Older

Recent Articles

• O2Gold Expands Acquisition Plans for Quebec Aur Property
• Brazil Potash Celebrates Successful Initial Public Offering
• ISS Endorses Director Nominees for Carver Bancorp, Inc.
• Deadline for Shareholder Distribution Approval Announced by LWP
• Axis Auto Finance Inc. Annual Meeting Voting Results Overview
• Fluent, Inc. Secures $5.75 Million Through Direct Offerings
• The Future of Silicon Photonics: Trends and Insights for Growth
• Expansion of Managed Services Market in Saudi Arabia Forecasted
• Cloud ERP Market Growth Driven by AI and Digital Transformation
• Exploring the Growth of the Titanium Market and AI's Impact
• Syntheia: Transforming Customer Engagement with AI Solutions
• Photonics Market Growth Forecast: Major Innovations Ahead
• Strategic Management Transition at Premier American Uranium
• Financial Overview of Patagonia Gold for Q3 2024
• First Savings Financial Group Declares Quarterly Dividend for 2024
• Anoto Group Introduces Its Latest Prospectus for Investment Opportunities
• Inovalis REIT Moves Forward with €18.2 Million Property Sale
• State Street Leadership Prepares for Goldman Sachs Conference
• XTM Inc. Celebrates Impressive Q3 2024 Performance with Growth
• Investors Excited for Lightspeed's Upcoming Conference Participation
• Emerging Trends in Cannabis Testing Market Boost Growth
• Halmont Properties' Strong Q3 Performance and Future Outlook
• Brookfield Infrastructure Announces Major Subordinated Note Deal
• Investigation Launched Against Customers Bancorp, Inc. Amid Losses
• Red White & Bloom Achieves Major Growth in Q3 Financials
• Cue Biopharma Welcomes New Chief Development Officer
• WeRide Inc. Launches GXR Robotaxi Platform and Strategic Growth
• Aspen Insurance's Preference Shares Redemption Announcement
• Chemours Successfully Reprices U.S. Dollar Term Loan Facility
• Understanding the Walgreens Boots Alliance Shareholder Settlement
• Innovative Mobile MRI Scanner Revolutionizes Healthcare Imaging
• Amgen Leadership Set to Speak at Key Healthcare Conference
• JB Perrette to Share Insights at Upcoming TMT Summit Event
• Neuberger Berman Real Estate Fund Declares Monthly Dividend
• Neuberger Berman Energy Fund Declares Monthly Cash Distribution
• Neuberger Berman Connectivity Fund Updates Share Distributions
• Neuberger Berman High Yield Strategies Fund Declares Monthly Payout
• Sirios Resources Plans Key Private Placements to Boost Growth
• TransCode Therapeutics Implements 1-for-33 Reverse Stock Split
• Aspen Insurance Announces Significant Preference Share Dividends
• PGIM High Yield Funds Announce Monthly Distributions
• iClick Interactive's Strategic Merger with Amber DWM Explained
• Reflecting on World AIDS Day: A Call to Action for Hope
• A21's Campaign Against Human Trafficking Hits New Heights
• Verve Therapeutics Expands Talent with New Stock Grants
• Globus Maritime Limited's Q3 2024 Financial Overview
• AI Transportation Acquisition Corp Shifts Focus After Agreement Ends
• ACM Research Engages Investors at the NYC Summit 2024 Event
• Triumph Financial Declares Dividend for Series C Preferred Stock
• Future Vision II and Viwo Technology Join Forces in Exciting Merger